Sofia Sees Hope is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind, but we invite all members of our community, including those in research, industry, and the regulatory communities to join any of the sessions, as we look ahead to a common goal of advancing treatments for rare retinal disease.
Monica Roy is Vice President, Clinical Development-Ophthalmology for Editas Medicine. She has focused her career on ophthalmic drug development. She has led teams through all phases of clinical development, regulatory approval, commercial launch, and life cycle management. Her experience includes leading the development of ophthalmic gene therapy programs for age related macular degeneration and diabetic retinopathy, leading the successful approval of Xiidra for dry eye disease, and most recently leading gene editing programs in inherited retinal disease.
Currently Editas is in trials with EDIT-101, a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10) (CEP290).